Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

The therapeutic landscape in the treatment of advanced/metastatic renal cell cancer has evolved over the last 2 years with the advent of immune checkpoint inhibitors. In 2018 and 2019, marketing authorisations valid throughout the European Union were issued for nivolumab and ipilimumab dual checkpoi...

Full description

Bibliographic Details
Main Authors: Daniela Melchiorri, Jonas Bergh, Francesco Pignatti, Didier Meulendijks, Paula Hennik, Bjorg Bolstad, Luca Moscetti, Jorge Camarero, Filip Josephson, Maja Sommerfelt Grønvold, Jan Sjoberg, Mihaela Botezatu, Jorn Mulder, Ana Trullas Jimeno, Nikolaos Zafiropoulos, Harald Enzmann
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/5/4/e000856.full

Internet

https://esmoopen.bmj.com/content/5/4/e000856.full

Similar Items